PeerView Oncology

 

PeerView Oncology
Avatar

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Mets: Which EGFR TKIs to Consider and How to Combine Them?

By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
107 views
May 28, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam
Lung
17:03
PeerView Oncology

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung A…

Feat. E. Garon, J. Heymach
15:20
PeerView Oncology

Locally Advanced and Early NSCLC IO Update: Will IO Change the Multi…

Feat. B. Stiles
15:18
PeerView Oncology

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in C…

Feat. S. Patel
02:22
PeerView Oncology

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or C…

Feat. S. Patel, M. Ahluwalia, K. Beal
05:24
PeerView Oncology

64 y/o Female With Newly Diagnosed Stage 4 NSCLC, EGFR exon 19 Mutat…

Feat. S. Patel, M. Ahluwalia, K. Beal
17:21
PeerView Oncology

Management of EGFR-Mutant Lung Cancer With Central Nervous System Me…

Feat. S. Patel, M. Ahluwalia, K. Beal
04:37
PeerView Oncology

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Me…

Feat. S. Patel, M. Ahluwalia, K. Beal